Literature DB >> 2537148

Effects of injection routes of growing tumors and PSK or OK-432 on antiproliferative activity of mouse serum.

C Ryoyama1, K Ryoyama.   

Abstract

The present study examined the effects of various treatments on the antiproliferative activity of mouse serum. Its activity was estimated against the growth of EL4 tumor cells and L929 cells and against splenic blastogenesis in culture. The activity varied among mouse strains tested and among individuals in any strain. However, normal outbred NIH Swiss mice showed the highest activity among the strains and the least variation among individuals. The activity of serum from NIH Swiss mice constantly decreased 7 or 14 days after an injection of 10(6) Ehrlich or sarcoma 180 tumor cells subcutaneously in the right-hind footpad, intradermally in the right side of the chest or into the palm. Other routes, such as intraperitoneal, intravenous in the tail vein, subcutaneous in the right side of the chest and intramuscular in the left thigh, however, hardly affected the activity. The activity also decreased 7 days after an injection into the footpad of a biological response modifier such as PSK or OK-432. The antiproliferative activity of mouse serum seem to depend on macrophages but not natural killer-cell activity, because treatment with silica but not anti-(asialo-GM1) antibody totally reduced the activity. The active fraction was heat-stable (100 degrees C, 30 min) and its molecular mass was 127-140 kDa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537148     DOI: 10.1007/bf00199109

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Relationship between tumour growth rate and proteic variations in interstitial subcutaneous fluid and serum: possible thymic control.

Authors:  D Vaillier; J Vaillier; P Bischoff
Journal:  Eur J Cancer       Date:  1977-09       Impact factor: 9.162

2.  Cytotoxic factor from peritoneal cells: purification and characteristics.

Authors:  D E Sintek; W B Pincus
Journal:  J Reticuloendothel Soc       Date:  1970-12

3.  Regulation of delayed-type hypersensitivity. I. T suppressor cells for delayed-type hypersensitivity to sheep erythrocytes in mice.

Authors:  F Y Liew
Journal:  Eur J Immunol       Date:  1977-10       Impact factor: 5.532

Review 4.  Humoral immunosuppressive factors.

Authors:  S R Cooperband; R Nimberg; K Schmid; J A Mannick
Journal:  Transplant Proc       Date:  1976-06       Impact factor: 1.066

5.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

6.  Purification and characterization of a mouse serum protein with growth inhibitory properties in vitro against tumor cell lines.

Authors:  S Gundersen; E Paus; S Funderud
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1983-04

7.  Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice.

Authors:  P H Koo
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

8.  Human platelets exert cytotoxic effects on tumor cells.

Authors:  G M Ibele; N E Kay; G J Johnson; H S Jacob
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

9.  Evidence for the presence of an antitumor factor in serum of normal animals.

Authors:  S Green; M A Chiasson; R G Shah
Journal:  Cancer Lett       Date:  1979-04       Impact factor: 8.679

10.  Differences in tumour necrosis factor productive ability among rodents.

Authors:  K Haranaka; N Satomi; A Sakurai
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

View more
  2 in total

1.  Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide.

Authors:  K Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.

Authors:  D Characiejus; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.